Interferon alpha-2a

Drug Profile

Interferon alpha-2a

Alternative Names: Roferon-A

Latest Information Update: 19 Sep 2011

Price : $50

At a glance

  • Originator Roche
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Marketed Chronic myeloid leukaemia; Cutaneous T cell lymphoma; Hairy cell leukaemia; Hepatitis C; Kaposi's sarcoma; Malignant melanoma; Non-Hodgkin's lymphoma; Renal cancer

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 01 Oct 2007 Withdrawn for Chronic myeloid leukaemia in USA (unspecified route)
  • 01 Oct 2007 Withdrawn for Hairy cell leukaemia in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top